Compare LICN & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LICN | OSRH |
|---|---|---|
| Founded | 2004 | N/A |
| Country | China | United States |
| Employees | N/A | 22 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2M | 17.9M |
| IPO Year | 2021 | N/A |
| Metric | LICN | OSRH |
|---|---|---|
| Price | $1.05 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 908.8K | 686.5K |
| Earning Date | 04-28-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $0.30 |
| 52 Week High | $9.49 | $1.24 |
| Indicator | LICN | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 50.26 |
| Support Level | $0.77 | $0.40 |
| Resistance Level | $1.76 | $0.45 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 39.52 | 43.44 |
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational, and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and the sales of financial and taxation training software.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.